Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 6/2021

01-12-2021 | Endoscopy | Case Report

Olmesartan-associated sprue-like enteropathy diagnosed by capsule endoscopy and double balloon endoscopy

Authors: Daisuke Taguchi, Takashi Ibuka, Masamichi Arao, Taku Mizutani, Noritaka Ozawa, Masaya Kubota, Yohei Shirakami, Makoto Shiraki, Hiroshi Araki, Masahito Shimizu

Published in: Clinical Journal of Gastroenterology | Issue 6/2021

Login to get access

Abstract

Sprue-like enteropathy associated with olmesartan is characterized by villous atrophy in the duodenum. We report the case of an 81-year-old woman diagnosed with olmesartan-associated sprue-like enteropathy with no villous atrophy in the duodenum. The patient had been taking olmesartan for 10 years and complained of diarrhea and weight loss. Despite undergoing general treatment for 2 months, her symptoms showed no improvement. Gastrointestinal endoscopy and pathological findings showed no villous atrophy in the duodenum. However, villous atrophy was observed in the small intestine by capsule endoscopy. Pathological biopsy with double balloon endoscopy provided a definitive diagnosis. Diarrhea improved with the discontinuation of olmesartan and weight increased within a week of withdrawal. After the improvement of clinical symptoms, both endoscopic and pathological findings of villous atrophy in small intestine showed improvement.
Literature
1.
go back to reference Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87:732–8.CrossRef Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87:732–8.CrossRef
2.
go back to reference Burbure N, Lebwohl B, Arguelles-Grande C, et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–34.CrossRef Burbure N, Lebwohl B, Arguelles-Grande C, et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–34.CrossRef
3.
go back to reference Ghaith J, Raslan IA, Szilagyi A, et al. Case of olmesartan-associated enteropathy and transient positive antitissue transglutaminase serology. BMJ Case Rep. 2018;11:e225518.CrossRef Ghaith J, Raslan IA, Szilagyi A, et al. Case of olmesartan-associated enteropathy and transient positive antitissue transglutaminase serology. BMJ Case Rep. 2018;11:e225518.CrossRef
4.
go back to reference Naik DK, Martelli MG, Gonzalo DH, et al. An atypical case of chronic diarrhoea: olmesartan-induced sprue-like enteropathy. BMJ Case Rep. 2015;2015:bcr2015212318.CrossRef Naik DK, Martelli MG, Gonzalo DH, et al. An atypical case of chronic diarrhoea: olmesartan-induced sprue-like enteropathy. BMJ Case Rep. 2015;2015:bcr2015212318.CrossRef
5.
go back to reference Theophile H, David XR, Miremont-Salame G, et al. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis. 2014;46:465–9.CrossRef Theophile H, David XR, Miremont-Salame G, et al. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis. 2014;46:465–9.CrossRef
6.
go back to reference Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40:1103–9.CrossRef Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40:1103–9.CrossRef
7.
go back to reference Rondonotti E, Spada C, Cave D, et al. Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study. Am J Gastroenterol. 2007;102:1624–31.CrossRef Rondonotti E, Spada C, Cave D, et al. Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study. Am J Gastroenterol. 2007;102:1624–31.CrossRef
8.
go back to reference Silva BMD, Neves SJ, Martinez AG, et al. Enteropathy associated with olmesartan. GE Port J Gastroenterol. 2016;23:96–100.CrossRef Silva BMD, Neves SJ, Martinez AG, et al. Enteropathy associated with olmesartan. GE Port J Gastroenterol. 2016;23:96–100.CrossRef
9.
go back to reference Gonakoti S, Khullar S, Rajkumar A. Olmesartan associated enteropathy: a rare underdiagnosed cause of diarrhea and weight loss. Am J Case Rep. 2019;20:111–6.CrossRef Gonakoti S, Khullar S, Rajkumar A. Olmesartan associated enteropathy: a rare underdiagnosed cause of diarrhea and weight loss. Am J Case Rep. 2019;20:111–6.CrossRef
10.
go back to reference Abdelghany M, Gonzalez L 3rd, Slater J, et al. Olmesartan associated sprue-like enteropathy and colon perforation. Case Rep Gastrointest Med. 2014;2014:494098.PubMedPubMedCentral Abdelghany M, Gonzalez L 3rd, Slater J, et al. Olmesartan associated sprue-like enteropathy and colon perforation. Case Rep Gastrointest Med. 2014;2014:494098.PubMedPubMedCentral
11.
go back to reference Uehara T, Ikusaka M, Ohira Y, et al. Olmesartan-induced enteropathy manifesting as Wernicke-Korsakoff syndrome. Intern Med. 2016;55:3675–8.CrossRef Uehara T, Ikusaka M, Ohira Y, et al. Olmesartan-induced enteropathy manifesting as Wernicke-Korsakoff syndrome. Intern Med. 2016;55:3675–8.CrossRef
Metadata
Title
Olmesartan-associated sprue-like enteropathy diagnosed by capsule endoscopy and double balloon endoscopy
Authors
Daisuke Taguchi
Takashi Ibuka
Masamichi Arao
Taku Mizutani
Noritaka Ozawa
Masaya Kubota
Yohei Shirakami
Makoto Shiraki
Hiroshi Araki
Masahito Shimizu
Publication date
01-12-2021
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 6/2021
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-021-01514-3

Other articles of this Issue 6/2021

Clinical Journal of Gastroenterology 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.